By Carlos Martinez, Life Science Leader
March 1, 2019
Holding yourself to the financial standards of a public life sciences company when your venture is still private or even in the prerevenue stages might not seem like the top priority to many young companies, but looking at your business through the eyes of the Securities and Exchange Commission (SEC) can make a big difference when it comes time to go public.
With thousands of businesses and more than $108 billion in revenue estimated last year, the life sciences industry has been enjoying a time of growth for the past several years, but economic conditions will likely cause that to slow down in the coming years, according to a study by IBISWorld. This tightening could make for a more competitive M&A landscape in the near term, and executives who have their ducks in a row will be more likely to prevail.
Read the full article here.